ROCURONIUM BROMIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROCURONIUM BROMIDE (ROCURONIUM BROMIDE).
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, blocking acetylcholine binding and inhibiting muscle contraction.
| Metabolism | Primarily hepatic via CYP450 (minor), but major pathway is deacetylation by plasma esterases? (Note: Actually rocuronium is mostly eliminated unchanged in bile and urine; minimal hepatic metabolism). |
| Excretion | Renal: 33% unchanged; Biliary/fecal: 33% (as parent and metabolite); Hepatic metabolism: ~10-20%; remainder: unknown |
| Half-life | Terminal elimination half-life: 1.4-2.4 minutes (distribution half-life: 3-5 minutes); recovery index (25-75%): 12-16 minutes; clinical duration (dose-dependent): 30-45 minutes (0.6 mg/kg) to 70-90 minutes (1.2 mg/kg) |
| Protein binding | ~30% bound; primarily to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | Vdss: 0.25-0.3 L/kg; Vdc: 0.03-0.06 L/kg (central compartment); reflects extracellular fluid distribution |
| Bioavailability | IV: 100% (not bioavailable orally due to gastrointestinal hydrolysis; no IM formulation approved; some data suggest IM 0.6-1 mg/kg: onset 3-4 min, duration up to 80 min) |
| Onset of Action | IV: 0.6 mg/kg: 1-1.5 minutes (intubation at 1.5-2 min); 1.2 mg/kg: 45-60 seconds |
| Duration of Action | IV (0.6 mg/kg): 30-45 minutes (clinical relaxation); 1.2 mg/kg: 68-95 minutes; recovery to 25% twitch: 25-45 min (0.6 mg/kg); prolonged in renal/hepatic impairment |
0.6 mg/kg IV bolus for intubation; maintenance: 0.1-0.2 mg/kg IV bolus as needed or continuous infusion 5-10 mcg/kg/min.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for GFR >30 mL/min; for GFR 10-30 mL/min, consider extended duration; for GFR <10 mL/min, use with caution and monitor for prolonged effect, no specific dose reduction. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: consider 50% dose reduction and monitor; Child-Pugh C: avoid or use with extreme caution, prolonged duration expected. |
| Pediatric use | Intubation: 0.6-1.2 mg/kg IV; maintenance: bolus 0.1-0.2 mg/kg or infusion 5-10 mcg/kg/min. Infants and neonates may require higher initial doses (0.6-1.0 mg/kg). |
| Geriatric use | Consider reduced initial dose (0.45-0.6 mg/kg) and titrate carefully due to increased sensitivity and prolonged duration; monitor neuromuscular blockade. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ROCURONIUM BROMIDE (ROCURONIUM BROMIDE).
| Breastfeeding | No human data available. M/P ratio unknown. Low oral bioavailability suggests minimal infant exposure. Caution advised; consider waiting 4-6 hours after dose before breastfeeding. |
| Teratogenic Risk | Insufficient human data. Animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if benefit outweighs risk. First trimester: avoid unless necessary. Second/third trimesters: possible fetal muscle relaxation if given near delivery. |
| Fetal Monitoring |
■ FDA Black Box Warning
Should be administered by experienced clinicians familiar with neuromuscular blocking agents and their complications. Resuscitative equipment must be immediately available. Reversal agents (e.g., sugammadex, neostigmine) should be available.
| Serious Effects |
["Hypersensitivity to rocuronium or bromide","Contraindicated for use without adequate facilities for intubation and ventilation"]
| Precautions | ["Anaphylaxis risk especially in patients with prior hypersensitivity","Residual neuromuscular blockade requiring monitoring of twitch response","Prolonged use may lead to muscle weakness/myopathy in ICU","Increased sensitivity in patients with neuromuscular diseases (e.g., myasthenia gravis)","Electrolyte disturbances (e.g., hypokalemia) may potentiate effects"] |
Loading safety data…
| Monitor maternal vital signs, oxygen saturation, and neuromuscular function (train-of-four). Fetal heart rate monitoring if used near delivery; assess for neonatal respiratory depression or muscle weakness at birth. |
| Fertility Effects | No known effects on fertility in animals or humans. Transient neuromuscular blockade does not impair long-term reproductive function. |